side effects retatrutide Research Unapproved weight loss drug retatrutide
Description
To learn more about compounded semaglutide, check out this blog
et al., 2021
J Clin Invest (2008) 118(11):3693700.10.1172/JCI36461 28 WuTZhaoBRBoundMJChecklinHLBellonMLittleTJet alEffects of different sweet preloads on incretin hormone secretion, gastric emptying, and postprandial glycemia in healthy humans
And so these were originally type 2 diabetes treatments, and now they have since moved on to become weight-loss treatments
Lower net acquisition costs for GLP-1 medications would strengthen the economic case for maintaining or adding GLP-1 coverage for obesity
In short, the research showed that patients with type 2 diabetes or who were overweight/obese and taking GLP-1 receptor agonists were at a higher risk of developing NAION
